Abstract

A phase 1B/2 trial of avelumab and pepinemab as second line for metastatic pancreatic adenocarcinoma

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call